卡培他滨联合多西紫杉醇治疗转移性乳腺癌的临床观察

Clinical observation on adjuvant therapy with capecitabine and docetaxel for women with metastatic breast cancer

为了探讨卡培他滨和多西紫杉醇联合方案治疗转移性乳腺癌的疗效及不良反应，29例转移性乳腺癌患者接受卡培他滨和多西紫杉联合方案化疗。卡培他滨2．0g／m^2，d1～d14；多西紫杉醇35mg／m^2，d1、d8、d15。21d重复，化疗2个周期以上。结果示29例患者入选，2例出组，27例可供评价疗效，29例可评价不良反应。有效率为51．9％（14／27），获益率为88．9％（24／27）；主要不良反应为手足综合征、皮肤色素沉着、白细胞减少、血小板减少、血红蛋白降低、恶心呕吐、口腔炎、腹泻、肝功能损害、脱发、心脏毒性、末梢神经毒性、过敏反应等。初步研究结果提示，对蒽环类药物和（或）紫杉醇治疗失败的转移性乳腺癌，卡培他滨联合多西紫杉醇是一种新的选择方案。

The objective of this study was to evaluate the response and the adverse effects of adjuvant therapy with capecitabine and docetaxel for women with metastatic breast cancer. The women with metastatic breast cancer were treated with 2.0 mg/m^2 of capecitabine d1-d14 and 35 mg/m^2 of docetaxel d1 ,d8 ,d15, every 21 days for 2 or more courses. Twenty-nine patients with metastatic breast cancer were enrolled, 2 withdrew. 27 were evaluable. The response rate was 51.9% and the benefit rate was 88. 9%. The main adverse effects included hand-foot syndrome, skin pigmentation, leucopenia, plate-reduction, hemo-reduction, nausea and vomitting, stomatitis,diarrhoea, hepatic function lesion, alopecie, cardiotoxic, neurotoxicity, anaphylaxis and so. In conclusion, this regimen can be applied to the women with metastatic breast cancer refractory to anthracyclines and/or paclitaxel.